Aptevo Therapeutics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aptevo Therapeutics Inc. on February 18, 2022. The report discloses the entry into a material definitive agreement regarding the issuance of common stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate transaction rather than periodic financial performance.
Material Changes and Agreements
- Purchase Agreement: On February 16, 2022, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC.
- Securities Issuance: The agreement allows for the issuance of shares of the Company's common stock, par value $0.001 per share.
- Registration: A prospectus supplement was filed with the SEC on February 18, 2022, under the Company's Shelf Registration Statement on Form S-3 (File No. 333-258758).
- Legal Opinion: Goodwin Procter LLP issued a legal opinion regarding the shares issuable under the agreement.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of the material agreement.
Key Facts for Investor Verification
- Verify the total number of shares and the purchase price per share in the full Purchase Agreement with Lincoln Park Capital Fund, LLC.
- Review the prospectus supplement filed under Form S-3 (File No. 333-258758) for dilution impact and use of proceeds.
- Confirm the current cash position of the Company to assess the necessity of this capital raise.